PsychRounds: The Psychiatry Podcast

Join us as we share some of our mistakes throughout this recording process.

Join us today as we briefly discuss some of the most common claims made against the use of lithium. As always, these are our personal opinions, not medical advice. Always consult your physician for appropriate guidance.

Join us as we briefly talk about Lithium, a medication frequently used in psychiatry!

Join us on our first episode covering an over-the-counter supplement. We will be discussing a lavender oil extract that is branded as Calm-Aid (Silexan).

Join us as we explore some of the non-pharmacologic treatments for Bipolar Disorder.

Dive into the complexities of treating bipolar disorder with pharmacology. Discover the critical distinctions between managing acute mania and depressive episodes. Explore various antipsychotic medications and their FDA-approved uses, emphasizing tailored drug selection for optimal outcomes. Learn about the importance of psychosocial functioning beyond traditional symptom tracking. Plus, find out how sleep plays a pivotal role in treatment decisions, enhancing overall patient quality of life. This discussion showcases the nuanced world of bipolar pharmacotherapy.

Join us as we continue our series on Bipolar Disorder. Today, we will be discussing a few of the proposed theories in regards to its pathophysiology.

Join us for another brief conversation. Today, we will be discussing Bipolar disorder and it's associated screening.

Dive into the world of Vortioxetine, a notable antidepressant that's shaking things up in the treatment of major depressive disorder! Discover its unique serotonin-modulating properties and potential cognitive benefits. The discussion reveals challenges like insurance woes and high costs, alongside insights into side effects and demographic advantages. Plus, look ahead to future topics on bipolar disorder, addressing screening and treatment strategies. It's a lively exploration of mental health innovation!

Dive into the world of Vilazodone, also known as Viibryd, exploring its unique properties as a serotonin partial agonist and reuptake inhibitor. Discover how it compares to Buspirone, particularly in reducing pill burden and addressing sexual side effects. The discussion also highlights the FDA's opinions on its marketing claims and its effectiveness in treating depression. With insights into new developments like Jepron and advancements in antidepressant efficacy, the conversation is a deep dive into the evolving landscape of psychiatric treatment.